Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,097 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial.
Gupta V, Oh S, Devos T, Dubruille V, Catalano J, Somervaille TCP, Platzbecker U, Giraldo P, Kosugi H, Sacha T, Mayer J, Illes A, Ellis C, Wang Z, Gonzalez Carreras FJ, Strouse B, Mesa R. Gupta V, et al. Among authors: ellis c. Leuk Lymphoma. 2024 Jul;65(7):965-977. doi: 10.1080/10428194.2024.2328800. Epub 2024 Mar 19. Leuk Lymphoma. 2024. PMID: 38501751 Free article. Clinical Trial.
Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.
Harrison CN, Vannucchi AM, Recher C, Passamonti F, Gerds AT, Hernandez-Boluda JC, Yacoub A, Sirhan S, Ellis C, Patel B, Strouse B, Platzbecker U. Harrison CN, et al. Among authors: ellis c. Adv Ther. 2024 Sep;41(9):3722-3735. doi: 10.1007/s12325-024-02928-4. Epub 2024 Jul 11. Adv Ther. 2024. PMID: 38990433 Free PMC article. Clinical Trial.
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With Momelotinib.
Harrison CN, Mesa R, Talpaz M, Gupta V, Gerds AT, Perkins A, Goh YT, Fox ML, McLornan D, Palmer J, Foltz L, Vannucchi A, Koschmieder S, Passamonti F, Lee SE, Ellis C, Strouse B, Gonzalez Carreras FJ, Oh ST. Harrison CN, et al. Among authors: ellis c. Clin Lymphoma Myeloma Leuk. 2024 Oct 16:S2152-2650(24)02359-0. doi: 10.1016/j.clml.2024.10.001. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39516087 Free article.
Momelotinib: Mechanism of action, clinical, and translational science.
Vlasakakis G, McCabe MT, Ho YL, Ferron-Brady G, Martin P, Bentley D, Ellis C, Antonysamy M, Visser SAG. Vlasakakis G, et al. Among authors: ellis c. Clin Transl Sci. 2024 Aug;17(8):e70018. doi: 10.1111/cts.70018. Clin Transl Sci. 2024. PMID: 39189872 Free PMC article. Review.
Neuroendocrine neoplasms: Consensus on a patient care pathway.
Hooper J, Jervis N, Morgan L, Beckett V, Hand P, Higgs K, Munir A, Prinn J, Pritchard DM, Sarker D, Srirajaskanthan R, Ellis CB. Hooper J, et al. J Neuroendocrinol. 2024 Apr;36(4):e13380. doi: 10.1111/jne.13380. Epub 2024 Mar 12. J Neuroendocrinol. 2024. PMID: 38471798 Review.
2,097 results